Innovative Targeted Therapeutics from PhotoBiotics
Bespoke targeting agents for MRI imaging and cancer treatment. We call this OptiLink
About Us
PhotoBiotics Ltd is a multidisciplinary spin-out from Imperial College London UK which combines chemistry, photophysics, and biochemistry ... read more »
Technology / Pipeline
OptiLink is a unique and simple conjugation platform for better drug delivery in imaging and therapy. It enables multiple loading of drug molecules and imaging agents onto specifically bio-engineered antibody fragments... read more »
OptiLink technology is currently being used with photosensitiser innovations to create ProstaLite, a promising novel targeted light activated therapy for prostate cancer.
As our pipeline evolves, OptiLink will deliver novel targeted 'see and treat' agents to improve efficacy and tolerability of treatment, significantly shorten tumour treatment times, and improve quality of life for patients... read more »
Latest News
